Skip to main content
. 2021 Jul 2;10(7):1669. doi: 10.3390/cells10071669

Figure 2.

Figure 2

YTHDF1 is associated with the translation of CCNB1 and cell proliferation in co-mutant KRAS/TP53 lung cancer. (a) Flow chart for screening the differential translation efficiency between co-mut KRAS/TP53 and wildtype LUAD patients. (b,c) Plot showing the protein level (b) and translation efficiency (c) of cyclin B1 in four different mutation groups. (d) Spearman’s rank correlation between the YTHDF1 mRNA level and the cyclin B1 protein level in LUAD patients (n = 357). (e,f) Kaplan–Meier survival plot of LUAD patients grouped by the protein (e) and translation efficiency (f) patterns of cyclin B1 with a cutoff of median expression. (g) Multi-GSEA plot showing the top eight pathways enriched in KRAS/TP53-mut patients compared with the wildtype group. The p-values were calculated using the log-rank test or Wilcoxon rank-sum test (* p < 0.05; *** p < 0.001; **** p < 0.0001).